<DOC>
	<DOC>NCT01207635</DOC>
	<brief_summary>The goal of this study is to evaluate antiproliferative effects of Arimidex in ductal lavage fluids of Breast Cancer patients. Breast cancer is the leading cause of cancer incidence and the second leading cause of cancer mortality in women. Breast duct fluid provide biomarkers to aid in risk assessment of developing breast cancer.</brief_summary>
	<brief_title>Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>Patient must have a history of breast cancer. Patient must be scheduled to receive standard treatment with Arimidex for adjuvant hormonal management. Patient must be willing to undergo a duct lavage. Patient must sign an Informed Consent.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Arimidex</keyword>
</DOC>